The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

Job Opportunity at the University of Houston!

by

The University of Houston is now accepting applications for an Assistant or Associate Professor position in Chemical & Biomolecular Engineering.

The William A. Brookshire Department of Chemical & Biomolecular Engineering at the University of Houston (UH) seeks to hire a tenure-track or tenured faculty member at the rank of Assistant or Associate Professor under the Presidential Frontier Faculty Program with research interests in the field of Biomolecular Engineering, with Immunoengineering being the preferred focus area.

The Presidential Frontier Faculty Program is a university-wide integrated interdisciplinary hiring campaign that is overseen by central University leadership and encompasses hiring a large cohort of convergence research faculty to work on health, energy, sustainability, and security. Competitive candidates are expected to have a Ph.D. degree or equivalent when they start their position and show potential for exceptional research and excellence in teaching and service. The successful candidate will be appointed at a rank commensurate with accomplishments and expertise.

More information on the role, responsibilities and requirements can be found here.

A link for uploading application materials will be posted here: http://www.chee.uh.edu/about/open-positions

The Huston Antibody Science Talent Award competition is open!

by

The James S. Huston Antibody Science Talent Award is sponsored by The Antibody Society to recognize and encourage upcoming scientists in the field of Antibody Engineering and Therapeutics. Early career research scientists who have received an advanced degree (Ph.D., M.D., or equivalent) within the past ten (10) years are eligible for the Award. The scientist is recognized for making important contributions to the antibody field and/or the dissemination of antibody knowledge. The recipient will be invited to give a lecture on their work, which will be made available on-line on The Antibody Society’s website, and to give a lecture at the Antibody Engineering & Therapeutics conference in December 2022.

The award includes: international recognition of the scientist’s accomplishments, a $1500 USD prize, and travel costs and registration fees to attend the annual Antibody Engineering & Therapeutics conference in San Diego, California.

The nomination process details are here. The deadline for submission is September 15, 2022.

The Society has selected mAbs as its Official Journal!

by

The Antibody Society is pleased to announce that it has partnered with Taylor & Francis, a leading research publisher, to make mAbs the Society’s Official Journal. mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, and the regulation of therapeutics.

Since 2009, mAbs has published high quality reports, reviews, and perspective articles covering a range of antibody R&D topics, including:

  • Engineering and selection of antibody therapeutics, including antibody-drug conjugates, multispecific antibodies, and single-domain antibodies
  • Machine learning and artificial intelligence applications
  • Non-clinical studies of antibodies, such as mechanism of action studies, safety, and efficacy studies in animals
  • Manufacturing and formulation
  • Regulatory review of antibody therapeutics
  • Post-approval topics, such as markets

The journal’s 2021 Impact Factor is 6.440 and, in total, articles are downloaded at a rate of over 1 million per year. Articles in the current volume (14) can be found here.

Members of The Antibody Society receive a 10% discount on article publication charges using their member code.

We look forward to a productive partnership with Taylor & Francis.

Congratulations to our 2022 Antibody Research Competition winners!

by

The Antibody Society sponsors competitions each year to recognize and encourage the research activities of promising student and postdoctoral fellow members. We are pleased to announce the 2022 Antibody Research Competition winners:

 

 

 

 

Rodrigo García-Valiente (Amsterdam UMC, University of Amsterdam, the Netherlands)
Poster title: Understanding repertoire sequencing data through a multiscale computational model of the germinal center

Dr. Hayden Fisher (University of Southampton, UK)
Poster title: Hinge disulfides in human IgG2 CD40 antibodies modulate activity by regulation of conformation and flexibility

Information on past competitions and winners can be found here.

Register for our upcoming webinar on BLI and its use in anti-snake venom antibody discovery

by

Biolayer interferometry (BLI) is gaining popularity for protein and small molecule quantitation and kinetics research. The new advancements in biosensors, ease of use, reproducibility and low cost is driving its adoption. Even though BLI is one of the easiest of the tools, as with many other techniques, getting the best data depends on optimization of some key experimental factors. This webinar will discuss the best practices in BLI and result of such implementation by way of an example of screening of a broadly neutralizing antibody of snake venoms.

Snake envenomation results in over 100,000 deaths and 300,000 permanent disabilities in humans annually. Contemporary antivenoms are produced from the polyclonal serum of venom-immunized livestock and are specific to a single or narrow genetic range of related snakes. Could a broadly neutralizing monoclonal antibody, or a cocktail of a few broad components, provide protection from diverse snake venoms? Centi-3FTX-D09, originating from the B-cell memory of a human subject with an extensive history of diverse snake venom exposure, recognized a conserved neutralizing epitope of 3-finger toxins (3FTXs), a dominant snake neurotoxin. Four crystal structures of Centi-3FTX-D09 in complex with 3FTXs from mamba, taipan, krait, and cobra revealed the mechanism of broad neutralization to be epitope mimicry of the interface between these neurotoxins and their native host target, the nicotinic acetylcholine receptor. Centi-3FTX-D09 provided in-vivo protection against diverse 3FTXs and, in combination with the phospholipase inhibitor varespladib, protection against whole venom challenge for diverse, genetically distinct, elapid species.

About the Speakers

Register here!